Litcius/Paper detail

Adjunctive PCSK9 Inhibitor Evolocumab in the Prevention of Early Neurological Deterioration in Non-cardiogenic Acute Ischemic Stroke: A Multicenter, Prospective, Randomized, Open-Label, Clinical Trial

Wen Tian, Hua Cao, Xidan Li, Xing Gong, Xinting Yu, Dongyun Li, Jing Xie, Ying Bai, Dawei Zhang, Xiaohong Li, Ping Xu, Jiahui Liu, Bingwei Zhang, Xiaofei Ji, Huijie Dong

2025CNS Drugs16 citationsDOI

Topics & Concepts

MedicineInternal medicineClinical endpointStroke (engine)Modified Rankin ScaleAtorvastatinIntracerebral hemorrhageEvolocumabRandomized controlled trialAdverse effectGastroenterologySubarachnoid hemorrhageCholesterolLipoproteinIschemiaIschemic strokeMechanical engineeringApolipoprotein A1EngineeringLipoproteins and Cardiovascular HealthAcute Ischemic Stroke ManagementAntiplatelet Therapy and Cardiovascular Diseases
Adjunctive PCSK9 Inhibitor Evolocumab in the Prevention of Early Neurological Deterioration in Non-cardiogenic Acute Ischemic Stroke: A Multicenter, Prospective, Randomized, Open-Label, Clinical Trial | Litcius